A significant increase in IGF2 expression was further confirmed in vivo by ELISA of tumor lysates of intracranial GBM12 or GBM30 tumor-bearing mice treated with rHSVQ when compared to PBS control (Figure 1E). The gene discussed is IGF2; the disease is neoplasm.